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RESEARCH NOTE
A correction to the age-adjustment 
of the GH-2000 score used in the detection 
of growth hormone misuse
Dankmar Böhning1* , Walailuck Böhning2, Nishan Guha3, David A. Cowan4, Christiaan Bartlett4, 
Peter H. Sönksen2 and Richard I. G. Holt2
Abstract 
Objective: The GH-2000 biomarker test has been introduced by the World Anti-Doping Agency as a method of 
detecting growth hormone misuse in professional sport. The test involves the measurement insulin-like growth 
factor-I and the amino-terminal pro-peptide of type III collagen (P-III-NP) which increase in a dose-dependent manner 
in response to GH. These measurements are combined in sex specific formulae that include an age adjustment. The 
original age adjustment overcorrects the effect of age in male athletes and could potentially place older men at a 
disadvantage. The purpose of this note is to investigate the performance of a previously suggested correction term in 
two new and larger data sets.
Results: The GH-2000 score was calculated for 7307 samples obtained from 15 accredited WADA laboratories in 2017 
and 3916 samples measured at Drug Control Centre, King’s College London, UK between 2013 and 2017. The GH-2000 
scores were investigated for positive age effects using standard regression modelling. As previously, all analyses con-
firmed a positive age effect. Applying the earlier suggested correction term of 0.032 × age showed a significant over-
correction leading to a negative association of the GH-2000 score with age. We now suggest a smaller age correction 
of 0.020 × age, which corresponds to the smallest effect found in the earlier studies.
Keywords: GH-2000 score, Adjusting for age effects, Centring and norming of scores
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(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Growth hormone is not only a powerful anabolic agent 
of considerable therapeutic value but is also misused in 
sport for its anabolic and lipolytic properties and its use 
is banned by the World anti-doping agency [1–3].
The GH-2000 biomarker method to detect GH misuse is 
based on the measurement of the GH-sensitive biomark-
ers, insulin-like growth factor-I (IGF-I) and the amino-
terminal pro-peptide of type III collagen (P-III-NP), both 
of which rise following GH administration. The GH-2000 
score was initially developed using immunoassays that are 
no longer available [4, 5]. Although the original discrimi-
nant function has remained unchanged, the decision limits 
have been updated as further experience has been accu-
mulated and new assays have become available [6].
Currently, there are three IGF-I assays (LC–MS/MS, 
Immunotech, IDS) and two P-III-NP (ORION and Sie-
mens-Centaur) assays approved by WADA. For more 
details and background on these assays see [6]. As these 
assays do not give identical results, different GH-2000 
scores are obtained with each of the combinations and 
as a result the decision limits are different, depending on 
the assay pair used.
The GH-2000 score includes an age correction because 
GH secretion and its markers diminish with age; in the 
case of GH, its secretion falls by ~ 14% per decade. The 
original age correction was determined using samples 
from 813 elite athletes; however, we previously reported 
that when using the original correction, the GH-2000 
score showed a positive age effect in male athletes 
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competing at the Daegu World Athletics Championship 
in 2011. We proposed a correction term for inclusion in 
the GH-2000 score [7].
The aim of the current study is assess the effect of the 
original and updated age correction in two new large 
populations of elite male athletes.
Main text
The GH‑2000 score
The development of the GH-2000 score has been 
reported previously in [6, 7]. It has the theoretical or 
model form
where the coefficients β0,β1,β2,β3 have different val-
ues for male and female athletes. When coefficients are 
replaced by estimates the GH-2000 score for male ath-
letes is
and for female athletes
As the GH-2000 score showed positive age-depend-
ency for male athletes competing at the Daegu World 
Athletics Championship in 2011, an adjustment to age 
correction was suggested in [5] as follows:
This correction is only required for the male population of 
athletes as no age dependency was found for female athletes. 
When applying the corrected score (3) to the GH-2000 score 
data used in [5] the positive age effect was no longer seen.
We have investigated two larger data sets, which 
includes data on testing for growth hormone misuse 
using the GH-2000 methodology. The first one con-
tains results of serum IGF-I and P-III-NP and calculated 
GH-2000 score from 7307 analyses in men performed in 
15 accredited WADA laboratories. WADA made these 
data available to the GH-2004 team. We denote this 
data set as the 2017-WADA. The second data set stems 
from the Drug Control Centre, King’s College London, 
UK and contains 3916 analyses in men collected in the 
years 2013–2017. We denote this second data set as the 
(1)
GH-2000 score =β0 + β1log(IGF-I)
+ β2log(P-III-NP) + β3
/
age
(2)
GH-2000 score = − 6.586 + 2.100 log(IGF-I)
+ 2.905 log(P-III-NP) − 101.737
/
age
GH-2000 score = − 8.459 + 2.195 log(IGF-I)
+ 2.454 log(P-III-NP) − 73.666
/
age
(3)
GH-2000 score = − 6.586 + 2.100 log(IGF-I)
+ 2.905 log(P-III-NP)
− 101.737
/
age
− 0.032 (age − 25.09)
London Lab 2012–2017 data. These are the largest cur-
rent databases on GH-2000 scores available.
Results
Both available data sets were used to investigate any age 
effect in the GH-2000 score. Although different pairs of 
assays were used, the combination of the Immunotech-
ORION assays was most frequently used. In Fig.  1 and 
Figure S1 of Additional file  1, the positive age depend-
ency is clearly visible when the original GH-2000 score 
based on the combination of the Immunotech-ORION 
(2) is used. This is also true when the LC–MS/MS and 
Siemens assay combination is used in the 2017 WADA 
data set (Figure S4 of Additional file 1, panel a). When the 
additional correction term (3) is applied, we observed a 
significant negative age-affect in Fig. 2 and Figure S2, S4b 
of Additional file 1.
As the additional correction term (3) leads to over-
correction of the effect of age in both datasets, we have 
reconsidered the correction term 0.032 used in (3). It was 
developed as weighted average of the age-effects across 
the various assay combinations. The specific age-effect 
for the Immunotech-ORION combination in Table  1 
from [7] is 0.0202. We therefore propose using this value 
as the correction term as it is represents the Immuno-
tech-ORION specific age-effect. The adjusted GH-2000 
score then becomes:
If we apply this correction for the Immunotech-ORION 
assay combination in the 2017 WADA and the London 
Lab 2012–2017 data set, we see that the age-effect disap-
pears as illustrated in Fig. 3.
The age-correction of 0.020 which is implemented 
in the new adjusted GH-2000 score also works well for 
other assay combinations as Figures S3 and S5 of Addi-
tional file 1 show where (4) is applied to the LC–MS/MS 
and Siemens assay combination. It should be noted from 
Table 1 in [7] that 0.020 is also the smallest observed age-
affect. Hence we recommend this value instead of the 
previously suggested value of 0.032.
Discussion
We are proposing this revised age adjustment for only the 
male athlete population as the original age adjustment per-
formed appropriately for the female population in these 
new cohorts of athletes. The original GH-2000 discrimi-
nant function for women therefore remains unchanged.
(4)
GH-2000 score = − 6.586 + 2.100 log(IGF-I)
+ 2.905 log(P-III-NP)
− 101.737
/
age
− 0.02 (age − 25.09)
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It is clear that the age-effect correction suggested 
in [7] over-corrects and can introduce a negative 
age-affect, hence favouring older athletes in these 
two larger populations. We have demonstrated that 
our new proposed age-effect correction removes the 
positive age effect in the two newer datasets as well 
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Fig. 1 Uncorrected GH-2000 score (2) using the assay combination Immunotech and ORION in the 2017 WADA data set showing a significant 
positive age effect
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Fig. 2 Corrected GH-2000 score (3) using the assay combination Immunotech and ORION in the 2017 WADA data set showing a significant 
negative age effect
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as the Daegu World Athletics Championship data set 
used in [7].
This new correction term of 0.02 is consistent with the 
data set used in [7] as it is the specific term found for the 
Immunotech-ORION assay combination. Taken together 
with the correction of the age effect in the two new inde-
pendent datasets, this provides strong evidence through 
confirmation of the validity of the findings. It is impor-
tant to recognise that we are not using new estimates 
from the new two data sets, but are using the estimates of 
the age-effect found in [7].
Limitations
This newly proposed adjustment term needs to be moni-
tored in future data sets, either as part of routine moni-
toring, as in this case, or as part of designed studies.
In conclusion, we have created a small further age 
adjustment for male athletes to correct the age bias intro-
duced with the original discriminant formula. This has 
no effect on the decision limits and could be easily intro-
duced into anti-doping testing.
Additional file
Additional file 1. Additional figures.
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